
CODEXIS, INC.
93
Recent news highlights Codexis's financial results, strategic partnerships, and operational advancements in RNA manufacturing.
- Codexis reported a net loss for Q3 2026 but revenue exceeded expectations, reflecting ongoing growth in its business [N1].
- The company secured a $60 million loan facility to support its operations and expansion plans [N6].
- Codexis presented data validating its ECO Synthesis platform for siRNA production, underscoring its technological capabilities [N6].
- Partnerships with siRNA drug developers aim to advance next-generation RNA manufacturing technologies [N6].
- Codexis reaffirmed its 2026 guidance and plans to advance its ECO GMP manufacturing center, indicating focus on operational scale-up [N8].
Codexis, Inc. develops and commercializes engineered enzymes and biocatalysts for pharmaceutical, chemical, and industrial applications. The company leverages its proprietary CodeEvolver® technology platform to create enzymes that improve manufacturing processes, reduce costs, and enhance sustainability. Codexis's ECO Synthesis platform is a key technology for RNA-based drug manufacturing, including siRNA production. The company generates revenue primarily through product sales, partnerships, and licensing agreements. Codexis maintains a strong liquidity position with significant cash and short-term investments and has no material pending litigation as of the latest filings.
Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. Codexis, Inc. is a biotechnology company specializing in enzyme engineering and biocatalysis. The company reported $138.59 million in revenue for fiscal 2022 and a net loss of $8.13 million for Q3 2026. As of September 30, 2026, Codexis held $29.21 million in cash and $43.45 million in short-term investments, with a strong current ratio of 2.81. Recent developments include securing a $60 million loan facility and advancing its ECO Synthesis platform for siRNA production, alongside partnerships to enhance RNA manufacturing capabilities.
Codexis's advanced enzyme engineering capabilities and ECO Synthesis platform position it well within the expanding RNA therapeutics market. The company's partnerships with siRNA drug developers and recent $60 million loan facility support operational expansion and technology validation. Continued revenue growth and narrowing net losses in recent quarters indicate progress toward commercial scalability. Codexis's strong liquidity and absence of material litigation provide a stable financial foundation for executing its strategic initiatives.
Codexis has reported net losses in recent quarters, reflecting ongoing investment in technology development and commercialization. The biotechnology sector is competitive and subject to regulatory and technological risks that could impact product adoption and partnership success. Dependence on a limited number of partnerships and customers may pose concentration risks. Operational execution risks include scaling manufacturing capabilities and achieving sustainable profitability. Market volatility and funding availability could affect the company's financial flexibility.
Codexis's competitive advantage stems from its proprietary enzyme engineering technology platform, CodeEvolver®, which enables rapid development of customized biocatalysts. The company's ECO Synthesis platform for RNA manufacturing addresses growing demand in the biopharmaceutical sector, particularly for siRNA therapeutics. Strategic partnerships and collaborations with drug developers enhance Codexis's market position and provide access to emerging RNA technologies. The company's focus on sustainable and efficient manufacturing processes supports differentiation in the biotechnology industry.
• Financial Performance Risk: Codexis has reported net losses, indicating ongoing challenges in achieving profitability while investing in technology and manufacturing expansion.
• Market and Competitive Risk: The biotechnology and enzyme engineering markets are competitive and rapidly evolving, with risks related to technology adoption, regulatory approvals, and competitor innovations.
• Partnership Concentration Risk: The company's reliance on partnerships, particularly in RNA therapeutics, may expose it to risks if key collaborations do not progress as planned.
• Operational Execution Risk: Scaling manufacturing capabilities, including the ECO GMP manufacturing center, involves execution risks that could impact timelines and costs.
• Liquidity and Funding Risk: While current liquidity ratios are strong, future capital needs and market conditions could affect funding availability and financial stability.
Business trends: Continued revenue growth with narrowing net losses and expansion in RNA manufacturing technologies.
Execution milestones: Advancement of ECO GMP manufacturing center and validation of ECO Synthesis platform for siRNA production.
Key risks: Profitability challenges, competitive biotechnology landscape, partnership reliance, and operational scale-up execution risks.
Very high visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- Codexis, Inc. is a publicly traded company listed on Nasdaq under ticker CDXS [S2].
- The company operates in the biotechnology sector with a focus on enzyme engineering and biocatalysis technologies [N6].
- Codexis reported revenue of $138.59 million for the fiscal year ended December 31, 2022, as per its 10-K filing [S1].
- As of September 30, 2026, Codexis had cash and cash equivalents of $29.21 million and short-term investments of $43.45 million, totaling approximately $72.66 million in liquid assets [S2].
- The company reported a net loss of $8.13 million for the quarter ended September 30, 2026, with basic and diluted EPS of -$0.08 per share [S2].
- Codexis had current assets of $95.77 million and current liabilities of $34.09 million as of September 30, 2026, resulting in a current ratio of 2.81 and a cash ratio of 2.13, indicating solid short-term liquidity [S2].
- Codexis is not currently involved in any material pending litigation or legal proceedings as of the latest filings [S2].
- Recent news highlights include Codexis reporting a Q3 loss but revenue exceeding expectations, securing a $60 million loan facility, and presenting data validating its ECO Synthesis platform for siRNA production [N1][N6].
- The company has partnerships to advance next-generation RNA manufacturing, including collaborations with siRNA drug developers [N6].
- Codexis has plans to advance its ECO GMP manufacturing center as part of its operational strategy [N8].
- The company has consistently reported quarterly losses but has shown revenue growth and narrowing net losses in recent quarters [N1][N8].
Generated 2026-11-13
- S1 | 2026-03-11 | 10-K
- S2 | 2026-11-12 | 10-Q
- N1 | 2026-11-12 | www.nasdaq.com | Codexis (CDXS) Reports Q3 Loss, Beats Revenue Estimates | https://www.nasdaq.com/articles/codexis-cdxs-reports-q3-loss-beats-revenue-estimates
- N2 | 2026-11-10 | www.nasdaq.com | Opus Genetics, Inc. (IRD) Reports Q3 Loss, Lags Revenue Estimates | https://www.nasdaq.com/articles/opus-genetics-inc-ird-reports-q3-loss-lags-revenue-estimates
- N3 | 2026-11-05 | www.nasdaq.com | Arcturus Therapeutics (ARCT) Reports Q3 Loss, Beats Revenue Estimates | https://www.nasdaq.com/articles/arcturus-therapeutics-arct-reports-q3-loss-beats-revenue-estimates
- N4 | 2026-11-04 | www.nasdaq.com | Revolution Medicines, Inc. (RVMD) Reports Q3 Loss, Beats Revenue Estimates | https://www.nasdaq.com/articles/revolution-medicines-inc-rvmd-reports-q3-loss-beats-revenue-estimates
- N5 | 2026-10-02 | www.nasdaq.com | Weekly Buzz: EW, ABBV, MIRM Score FDA Wins, AZN, NVO Strike Deals; LLY, KOD Report Data | https://www.nasdaq.com/articles/weekly-buzz-ew-abbv-mirm-score-fda-wins-azn-nvo-strike-deals-lly-kod-report-data
- N6 | 2026-09-28 | www.nasdaq.com | Codexis Partners With SiRNA Drug Developer To Advance Next-Generation RNA Manufacturing | https://www.nasdaq.com/articles/codexis-partners-sirna-drug-developer-advance-next-generation-rna-manufacturing
- N7 | 2026-08-18 | www.nasdaq.com | Codexis (CDXS) Q2 2026 Earnings Call Transcript | https://www.nasdaq.com/articles/codexis-cdxs-q2-2026-earnings-call-transcript
- N8 | 2026-08-12 | www.nasdaq.com | Codexis Q2 Net Loss Narrows; Reaffirms 2026 Guidance; Plans To Advance ECO GMP Manufacturing Centre | https://www.nasdaq.com/articles/codexis-q2-net-loss-narrows-reaffirms-2026-guidance-plans-advance-eco-gmp-manufacturing
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Generated by Valye SEC Pipeline Engine
.gif)


